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Gonorrhoea, a sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, remains a major 
public health issue worldwide with the World Health Organization (WHO) estimating that 87 million 
new cases of gonorrhoea occur annually[1]. Untreated gonorrhoea contributes to serious 
reproductive and sexual health sequelae, including pelvic inflammatory disease, infertility and an 
increased risk of transmission of HIV. Current international guidelines recommend ceftriaxone, with 
or without azithromycin, as treatment for gonorrhoea but this approach has been threatened by 
rising Minimum-Inhibitory Concentrations (MICs) in N. gonorrhoeae and the emergence of multi-
drug resistant strains[2].  Indeed, the emergence of antimicrobial resistance (AMR) in 
N. gonorrhoeae has represented a constant challenge to the management of the disease in both 
low- and high-income settings. The history of gonorrhoea treatment is characterised by the 
successive introduction of new therapeutic agents followed rapidly by the emergence of widespread 
resistance. Such a phenomenon has occurred with sulphonamides, penicillins, tetracyclines, 
macrolides, fluoroquinolones, and early-generation cephalosporins[3]. In light of the threat of AMR 
to the control of gonorrhoea, WHO has launched a global action plan including priority actions for 
gonorrhoea infection and AMR prevalence and incidence surveillance, national laboratory capacity 
strengthening, including the introduction of point-of-care tests (POCTs), and adapting national 
treatment guidelines to resistance patterns[4]. 
A number of strategies might be considered in order to combat the growing threat of AMR in N. 
gonorrhoeae. In common with other infectious diseases, the use of alternative or newer 
antimicrobial agents for treatment has been a priority area for research. In some regards the 
pipeline for gonorrhoea might be considered promising with a wide number of repurposed and 
newer agents undergoing trials. However, the challenges of developing agents that fit the desired 
profile of extremely high efficacy achieved with a single dosing regimen make identification of new 
agents challenging. Recent studies have evaluated Gentamicin[5], Solithromycin[6], Zoliflodacin[7] 
and gepotidacin[8]. The former two agents failed to achieve acceptable levels of cure in clinical trials 
whilst Phase 3 studies of the latter two agents are awaited. However, the historical evidence 
suggests that the benefit of any new agent is likely to be short-lived and that clinicians and policy 
makers should anticipate emergence of resistance to these agents within a relatively short time-
frame. An alternative therapeutic strategy would be to identify multi-dose regimens, as are 
commonly utilised in other infectious diseases and increasingly in the treatment of STIs, such as 
prolonged doxycycline for the treatment of Chlamydia trachomatis or extended treatment of 
Mycoplasma genitalium. 
 
Inherent in both current and emerging antimicrobial treatment strategies is the use of empiric 
therapy for patients presenting with urethritis, cervicitis or other syndromes consistent with 
gonorrhoea. The need for empiric therapy requires easy to administer, highly efficacious treatment 
regimes. An alternative strategy would be to deploy targeted antimicrobial therapy guided by the 
antimicrobial susceptibility data. Such a strategy might allow re-use of previously discarded 
therapies[9] and in turn, reduce the selection pressure on N. gonorrhoeae by diversifying the 
treatment regimens in use.  
 
To facilitate individualised treatment, it is necessary for clinicians to have access to reliable, accurate 
and rapid diagnostic tests. Culture is critical in gonorrhoea diagnosis for antimicrobial susceptibility 
testing, allowing phenotypic determination of resistance patterns and MICs. However, the sensitivity 
of culture is low and the turn-around time several days making it unhelpful for routine clinical care. 
In high-income settings, Nucleic Acid Amplification Tests (NAATs) are recommended for detection of 
infection because of their high sensitivity and specificity, and their relatively rapid turn-around time. 
There is increasing interest in the use of NAATs not only for diagnosis of infection, but also detection 
of AMR genes and to guide treatment strategies.  
 
In this issue of Clinical Infectious Diseases, Klausner and colleagues [KLAUSNER ARTICLE HERE] 
report how a genotype-testing NAAT could be implemented in a real-world setting. The authors used 
residual DNA from the diagnostic C. trachomatis/N. gonorrhoeae NAAT to perform a PCR targeting a 
point mutation in the gyrase A gene (gyrA), which is known to result in resistance to ciprofloxacin in 
N. gonorrhoeae. To confirm the association of genotypic testing with in-vitro susceptibility, they 
performed culture and determination of ciprofloxacin MICs. Individuals with asymptomatic 
gonorrhoea were recruited from sexual health clinics across seven cities in the United States of 
America, treated with a single oral dose of ciprofloxacin and re-tested for proof of cure five to ten 
days after treatment. As expected, all wild-type isolates had an MIC <1μg/ml. The results of the 
study clearly demonstrate that in the presence of a wild-type gyrA allele, ciprofloxacin remains a 
highly efficacious treatment for gonorrhoea with 100% microbiological cure in the patient 
population. Introduction of the test into routine clinical practice, as a second step assay following a 
diagnostic NAAT, would allow clinicians to bring ciprofloxacin back into their clinical armamentarium 
at a time when new approaches to the management of gonorrhoea are badly needed.  
 
It is worth considering the features of ciprofloxacin resistance in N. gonorrhoeae that make this 
approach viable. Importantly, the relationship between gyrA mutations and resistance is 
characterised by extremely high genotype-phenotype correlation. This means that presence of the 
mutation strongly predicts resistance, and that absence (a wild-type allele) strongly predicts a 
susceptible strain. Indeed, as Klausner and colleagues point out, a single point mutation predicted 
more than 98% of ciprofloxacin resistance in N. gonorrhoeae. This could allow genotypic AMR 
detection and resistance-testing guided therapy to become a part of the standard-of-care. How large 
an impact this strategy can be expected to have depends strongly on the proportion of cases, where 
if genotypic AMR detection was available, that ciprofloxacin would be a viable treatment for which 
will vary markedly across different regions of the world [3]. Such strong genotype-phenotype 
correlations are, however, not universal. In N. gonorrhoeae, the proportion of resistance conferred 
by different mutations varies markedly between different classes of agents such as 
fluoroquinolones, macrolides and extended spectrum cephalosporins [10].  
 
It is important we recognise the limitations of the approach utilised in this study. Enrolled patients 
were selected on the basis of an initial positive NAAT result, and had not received empiric therapy. 
Such an approach may be possible in high-income settings for asymptomatic individuals detected on 
screening, or even some symptomatic individuals, but would not be possible for patient populations 
where empiric therapy is commonly used (e.g. those with high loss to follow-up) or in low-income 
settings where treatment is often based on syndromic management due to lack of access to any STI 
diagnostic testing. Can the assay utilised in this study be multiplexed with near-patient diagnostic 
assays to provide a same day result and appropriate management? Can such assays and platforms 
be made available in low-income settings? Implementing resistance-based therapies would require a 
fundamental shift in the way in which sexual health services are delivered worldwide, but would be 
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